Our Commitment to Innovation
Since our launch in 1983, our commitment to innovation has been consistently proven with a demonstrated history of launching first-in-class or best-in-class products. Over 200 Octapharma Research & Development (R&D) scientists continuously explore new therapies based on human proteins, either purified from human plasma or produced by human cell recombinant technologies.
Our R&D activities occur in 6 centers of excellence in Europe (Vienna, Austria, Berlin, Frankfurt, Munich, Germany and Stockholm, Sweden). In 2012, Octapharma Biopharmaceuticals, an ambitious research facility dedicated to human cell based recombinant research commenced operations in Heidelberg, Germany.
R&D Team Structure
Our R&D team is divided into two key areas:
The R&D Plasma Group focuses on developing novel plasma-derived protein products and supporting lifecycle management of the existing Octapharma product portfolio.
The R&D Recombinant Group is dedicated to developing therapeutic human recombinant products and upscaling related production capabilities.